Abstract: Bioorthogonal chemistries are covalent reaction pairs that proceed in the presence of biological components with complete specificity. A suite of reactions has been described to date that provides scientists and engineers with diverse operational characteristics for different applications. Nanomaterials in particular have benefitted from these new capabilities, resulting in improved coupling efficiencies and multifunctionality. In this review, we will discuss the application of bioorthogonal chemistries to different nanomaterial systems, highlighting the advantages and limitations for use in bioconjugation. We will also describe how recent improvements in the reaction speed of catalyst-free bioorthogonal chemistries have enabled the successful coupling of nanomaterials directly to live cells. Using a recently developed reaction pair, tetrazine and trans -cyclooctene, the direct covalent coupling to cells has been shown to occur on time-scales that are relevant for biological studies and diagnostic applications and can even amplify nanomaterial binding greater than tenfold relative to traditional immunoconjugates. This powerful technique still maintains exquisite specificity, however, yielding robust results in clinical diagnostic applications using human tissue and blood samples. Future work will likely focus on further advancement of the in situ amplification technique, such as increasing nanomaterial binding, enabling multiplexed detection through the use of orthogonal reaction systems and extension to applications in vivo .
Introduction
Nanomaterials continue to generate significant interest in biomedical applications owing to their unique properties. For example, nanocarriers can provide protection, high cargo capacity, controlled release, and attractive pharmacokinetics/biodistribution [1] . Moreover, nanocrystals exhibit unique physical properties such as paramagnetisim [2, 3] , semiconductor fluorescence [4 -6] , plasmon resonance [7] , and photoluminescence upconversion [8, 9] that can be harnessed as exquisitely sensitive, stable, and/ or multiplexed detection signals. Finally, biomolecules can be conjugated to the surface of all types of nanomaterials to impart efficient and multivalent adhesion for molecular targets. Owing to these attributes, targeted nanomaterials present attractive diagnostic and therapeutic capabilities. However, to maximally exploit their potential, effective bioconjugation strategies are needed that are simple, fast, broadly applicable, have a small footprint, and are suitable for complex biological environments.
Bioorthogonal chemistries are a class of reactions whose cognate partners do not interfere with the functional groups endogenous to cells. This includes standard protein functional groups such as primary amine, thiol, carboxylic acid, and hydroxyl groups, as well as metabolic intermediates like aldehydes and ketones [1] . These recently developed chemistries offer greater control and flexibility for manipulating biological systems and, thus, are ideal for elucidating the biological processes or engineering-specific interactions within a complex cellular or tissue environment.
In this review, we discuss the development of bioorthogonal coupling reactions and highlight their use for probing biomolecule targets with nanomaterial sensors in biological systems. We describe how the growing suite of bioorthogonal chemistries is suited for different types of nanomaterials and targeting applications. Specifically, bioorthogonal chemistries have enabled more efficient and diverse modifications of nanomaterials and subsequent targeting to biomolecules. This includes recent applications in which the reactions, themselves, have been used for coupling nanoparticles to live cells in situ (i.e., direct labeling by covalent reaction). Finally, we discuss the clinical translation of bioorthogonal chemistry-based cell diagnostics. Future work in this area will improve the sensitivity of nanoparticle detection platforms as well as utilize multiple bioorthogonal chemistries simultaneously or in concert with classic chemistries for multiplexing capacity. Another promising advancement is the translation of bioorthogonal chemistries to in vivo systems for detection or drug delivery.
History of development
Taking inspiration from the classical Staudinger reaction, Saxon and Bertozzi [10] designed a chemoselective ligation between an azide and phosphine. Unlike the original reduction reaction whose intermediate hydrolyzes to form a primary amine and phosphine oxide, the modified Staudinger reaction introduces an electrophilic trap on the phosphine reactant. As a result, a stable amide bond forms after hydrolysis. Representing both the origins and future application goals for this reaction, it was named the Staudinger ligation. Utility in a biological setting was first demonstrated using azido-modified sugars that were metabolically incorporated onto cellular surfaces. Azide moieties were then specifically labeled by covalent reaction with a biotinylated phosphine and subsequent binding with fluorescein isothiocyanate (FITC)-avidin [10] . Owing to the small size of the azide reactant, modifications do not perturb the biomolecule. In addition, azide is entirely absent from biological systems. These advantages, along with the chemoselectivity of the reaction, have resulted in extensive use of the Staudinger ligation for labeling biomolecules [11] . Despite its effectiveness, the Staudinger ligation is limited by its relatively slow reaction kinetics and susceptibility to phosphine oxidation [11, 12] .
The copper-catalyzed Huisgen cycloaddition was developed to address the kinetic limitations of the Staudinger ligation, while still making use of azide as a reactant. This 1,3 dipolar cycloaddition yields a triazole linkage by reacting an azide with a terminal alkyne [13] . Without a catalyst, this reaction only proceeds at high temperatures. However, when catalyzed by reduced copper, or copper(I), the reaction proceeds at an accelerated rate at room temperature [14] . The copper-catalyzed azidealkyne cycloaddition (CuAAC) is efficient, selective, and proceeds over a broad pH range in aqueous solutions. For these reasons, the CuAAC reaction has become a valuable technique for surface modifications and protein labeling. The CuAAC has also been referred to as " click chemistry " or the " click reaction " . Unfortunately, the CuAAC has limited applicability for living systems because the Cu(I) catalyst is cytotoxic. Another limitation is that the Cu(I) affects the fluorescence yield of fluorescent proteins such as GFP. More directly relevant to this review, the CuAAC is not compatible with quantum dots because the Cu(I) catalyst nonreversibly quenches fluorescence [15] . Finally, care must be taken when achieving the reducing conditions required for Cu(I) because they can easily affect acid-labile species such as iron oxide nanocrystals.
As an alternative to metal catalysis, the Bertozzi group demonstrated that the introduction of ring strain into the alkyne moiety can effectively drive cycloaddition, but with a slower reaction rate [16] . In this catalyst-free approach, the bioorthogonal cycloaddition of geometrically strained alkyne, cyclooctyne, reacts with azide to form a triazole. This reaction is stable under physiological conditions, and cytotoxic effects were not observed after labeling azido sugars with a biotin-conjugated cyclooctyne. Though improved biocompatibility is certainly an advantage of the strain-promoted reaction, the slower reaction rate relative to CuAAC is limiting for some applications. The slow reaction has been addressed to some degree by modifying cyclooctyne with substituent groups such as monofluoriniated [17] and difluorinated cyclooctyne [18] . The addition of electron-withdrawing fluorine groups adjacent to the alkyne encourages reaction with azide. Cyclooctyne variations, such as 4-dibenzyocylooctynols (DIBO) [19] and biarylazacyclooctynones (BARAC) [20] , introduce aromatic rings to impose higher ring strain and, thereby, increase the reactivity of the alkyne. The improved reaction rates observed with DIBO-azide cycloaddition prompted Boons et al. to utilize DIBO for a strain-promoted nitrone cycloaddition [21] . Nitrone cycloadditions, though similar, offer faster kinetics than their azide counterparts on the order of sixfold.
To meet the needs of the most demanding biological applications, the groups led by Fox and Weissleder further accelerated catalyst-free capabilities by developing a set of reactions between 1,2,4,5-tetrazines (Tzs) and strained alkenes that proceeds via inverse-electron-demand DielsAlder cycloaddition [22 -25] . The strained dienophiles that have been tested include norbornene, cyclooctyne, cyclopropene, and trans-cyclooctene (TCO), each displaying varying reaction speeds. Modifying Tz substituents has also been shown to affect the reaction speed with TCO, as well as Tz stability in serum [26] . The extremely fast Owing to the potential solubility concerns for the dienephiles, particularly those with ring structures (TCO, cyclooctyne, cyclopropene), we do not recommend high-density modification of the nanoparticles. [26] .
reaction between Tz and TCO has enabled live cell labeling both in vitro [28] and in vivo [29, 30] . Interestingly, the TCO/Tz chemistry has been shown to be orthogonal to octyne-azide if a slower-reacting Tz is employed [31] . Despite the potential power of the TCO/Tz reaction, difficulty in synthesizing Tz had hindered widespread application. This problem was recently addressed though with the report of a series of 1,2,4,5-Tzs by metal salt-catalyzed formation from nitriles [32] .
The bioorthogonal chemistries that we will discuss in this review are summarized in Table 1 and the general reaction schemes are presented in Figure 1 . We will specifically focus on the application of these bioorthogonal chemistries to nanomaterial-based sensing applications. Successful nanomaterial detection strategies require advanced nanomaterial targeting for efficient binding and sensitive biomolecule detection. Nanomaterials should specifically recognize their biomolecule targets, yet have limited nonspecific binding, and should react rapidly. The speed and chemoselectivity of bioorthogonal reactions, as well as their widespread application to labeling functional groups in vivo, make them ideal for modifying nanomaterials with biomolecules and for targeting disease markers for diagnostic purposes.
Functionalization of nanomaterials with biomolecules using CuAAC
Early application of bioorthogonal chemistries to nanomaterials focused on the CuAAC at the time in which the " click reaction " was gaining popularity across biology and engineering. The high selectivity in complex biological surroundings, rapid reaction rate, mild aqueous conditions, and reproducible results made the reaction well suited for biocompatible nanoparticle modification. In some cases, researchers were even able to show that using " click " chemistry to functionalize nanoparticles could overcome the limitations that had previously hindered in vivo nanoparticle targeting, such as insufficient reaction efficiency, aqueous compatibility, and bio-inertness. Bosseliar et al. demonstrated the utility of the CuAAC reaction for modifying inorganic nanoparticles by functionalizing gold nanocrystals [33] . Previous attempts to employ this chemistry on gold nanoparticles were largely unsuccessful, leading to low yields [34] . The authors addressed previous problems using a homogenous water-THF solution to solubilize all the reactants and inert atmospheric conditions to prevent the oxidation of Cu(I). As a result, azido-terminated gold nanoparticles were successfully coupled to terminal alkynes to form 1,2,3-triazolyl linkages at near quantitative yield. A variety of terminal alkynes were investigated, including PEG-containing alkynes, which could assist in the biocompatibility of gold nanoparticles. All tested alkynes reacted with similar success.
The CuAAC chemistry has also been employed to construct small biomolecule libraries on nanoparticles. A panel including biotin, indocyanine dye, azo dye, taxane, and estradiol were modified with azide and coupled to alkyne-functionalized magnetic nanoparticles [35] . This procedure was facile, and the resulting triazole linkages were stable for several months.
The Bhatia group demonstrated the in vivo compatibility of " clickable " nanoparticles [36] . A tumor-targeting peptide, LyP-1, was decorated with alkyne and reacted via " click " chemistry to azide-magnetofluorescent nanoparticles (MFNP) to form LyP-1 nanoparticles. After intravenous injection into mouse tumor xenograft models, LyP-1-nano particles retained stability while circulating for over 5 h. LyP-1 nanoparticles directly bound to the p-32 target expressed by tumor cells, whereas untargeted nanoparticles were unable penetrate the tumor.
The in vivo compatibility of " click " conjugations also permitted the coupling of a positron emission tomography (PET) tracer to MFNP for trimodality imaging by PET, magnetic resonance imaging, and fluorescence molecular tomography [37] . The application of magnetic nanoparticles and fluorophores for molecular imaging has been Table 1. well explored; however, it is currently limited by in vivo detection thresholds. " Click " chemistry enabled facile addition of the PET tracer 18 F to magnetic nanoparticles, a labeling that has otherwise been chemically challenging because of the short half-life of the probe. The addition of the positron emitter lowered the detection threshold two-to fourfold for the trimodality nanoparticles relative to MRI and FMT and exhibited in vivo stability. Thorek et al. utilized CuAAC to investigate the coupling efficiency of the antibodies to magnetic nanoparticles in comparison to the alternatives. In fact, they demonstrated that CuAAC yields a higher antibody coupling density to nanoparticles than carbodiimide chemistry [38] . The superior " click " reaction coupled an average of almost seven antibodies per nanoparticle, while carbodiimide chemistry only yielded approximately three antibodies. The increased antibody density on CuAAC-derived magnetic nanoparticles directly resulted in increased binding efficiency for the molecular target due to higher avidity.
CuAAC has also been employed in tandem with expressed protein ligation (EPL) to couple magnetic nanoparticles to recombinant targeting ligands [39] . Expressed protein ligation is a site-specific protein modification technique that can offer controlled orientation of affinity molecules on the nanoparticle surface. This is useful to maximize binding efficiency for target molecules. However, previous attempts to use EPL for nanoparticle modification were plagued by low yields. In this study, a two-step approach using CuAAC with EPL significantly improved yield. A HER2-specific affibody with a C-terminus thioester was ligated to an alkynated fluorescent peptide via an N-terminus cysteine by EPL. The alkyne-modified affibody was then " clicked " via the intermediate peptide to azide-magnetic nanoparticles. The HER2 affibody-magnetic nanoparticles prepared by CuAAC-EPL bound to HER2-positive cancer cells more efficiently than the ones prepared with CuAAC alone or carbodiimide chemistry. The anti-HER2 affibody was also conjugated to liposomes and dendrimers in similar fashion to demonstrate the broad utility of this approach.
Catalyst-free bioorthogonal functionalization of nanomaterials
The application of bioorthogonal chemistries to nanomaterials has been dominated by the CuAAC reaction; however, reports using the catalyst-free alternatives are beginning to rise. In the case of quantum dots, catalyst-free chemistries are the only option because Cu(I) irreversibly quenches fluorescence. The Bawendi group was the first to demonstrate bioorthogonal modification of quantum dots using inverse-electron-demand Diels-Alder cycloaddition between Tz and norbornene [15] . Interestingly, as the norbornene used to modify the quantum dot does not coordinate with the zinc sulfide coating, unlike the thiol or amine functional groups, the bioorthogonal modification was more facile and efficient than the traditional bioconjugation strategies. Norbornene quantum dots were functionalized with Tz-modified epidermal growth factor (EGF), and the resulting conjugate was used to label EGF receptor (EGFR) on lung cancer cells for fluorescent imaging. Remarkably, the coupling chemistry was rapid enough to directly label cells in situ, as demonstrated by first targeting cells with Tz-EGF and then covalently reacting norbornene-quantum dots. Catalyst-free site-specific ligation has also been demonstrated using strain-promoted azide-alkyne cycloaddition [40] . This was accomplished by first expressing an anti-HER2 single-chain antibody (scFv) that was recombinantly expressed with an N-terminal serine residue. Through a series of mild reactions, the hydroxyl group on this serine was converted to a nitrone functionality for reacting with cyclooctyne. Indeed, the nitrone-scFv could be attached to DIBO-modified MFNPs, and the cycloaddition product selectively bound to its HER2 target leading to elevated fluorescence and decreased T 2 relaxation.
Though not yet tested with nanomaterials, genetically encoded TCO has been reported using the lipoic acid/ lipoic acid acceptor peptide system [41] .
Owing to the rapid kinetics of TCO/Tz Diels-Alder cycloaddition, Haun et al. adapted this chemistry for functionalizing MFNP with antibodies and compared the binding efficiency to the classic maleimide-thiol coupling [42] . The monoclonal antibodies were first decorated with one to two TCO residues via standard amine-reactive chemistry and then directly coupled to Tz-modified MFNPs. This was performed for the antibodies that were specific for the extracellular cancer biomarkers HER2, EGFR, and epithelial cell adhesion molecule (EpCAM). The nanoparticle immunoconjugates were then targeted to the cancer cells overexpressing the target proteins, and fluorescence was measured. The immunoconjugates prepared using TCO/Tz chemistry yielded comparable nanoparticle binding levels relative to the traditional maleimide-thiol coupling chemistry for two of the cases, but interestingly, the EpCAM signals were much greater.
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Figure 2 Overview of the two-step nanoparticle detection strategy (BOND-2). (A)
A biomarker of interest is targeted with a monoclonal antibody modified with TCO. Multiple Tz-modified nanoparticles are then covalently coupled to bound antibodies to achieve amplified nanoparticle binding. (B) Fluorescence intensity of labeled cells has the highest achievable signal using the BOND-2 strategy compared to the avidin/biotin two-step labeling or the one-step labeling using bioorthogonal chemistry (BOND-1). (Reprinted with permission from Ref. [42] . Copyright 2010 Nature Publishing Group.)
Covalent coupling of nanomaterials to cells using the Tz cycloaddition
Haun et al. investigated the capabilities of the exceptionally fast TCO/Tz reaction for covalent, in situ coupling of MFNP to live cells [42] . Using monoclonal antibodies that were heavily modified with TCO for pretargeting extracellular cancer biomarkers (HER2, EGFR, EpCAM), followed by the covalent reaction of Tz-MFNP, the theory that the antibody may be large enough and the covalent linkage small enough, to promote the attachment of multiple MFNP sensors was tested (Figure 2 ) . The antibody would, thus, act as a scaffold to amplify nanoparticle binding. This strategy was referred to as a two-step bioorthogonal nanoparticle detection (BOND-2), in comparison to using the TCO/Tz chemistry for antibody coupling prior to cell labeling (one-step BOND or BOND-1). Initial experiments demonstrated that modulating TCO loading on monoclonal antibodies resulted in a corresponding increase in nanoparticle binding. Binding saturation was not observed until approximately 20 reactive sites per antibody, and even at this high loading density, the affinity of the antibody was still unaffected. Charged fluorophores can affect antibody binding even at low loading levels, thus, the nonpolar TCO is very inert for protein bioconjugations. Most importantly, the high number of TCO reaction sites on the antibodies supported MFNP binding levels that exceeded direct immune conjugates prepared by BOND-1 or traditional maleimide-thiol chemistries. Using the BOND-2 scheme, MFNP signal was, thus, chemically amplified by attaching multiple nanoparticles per antibody scaffold, and this effect extended as high as 15-fold. Some signal amplifications was also observed when avidin-biotin binding was used for a similar two-step labeling procedure; however, the large size of avidin limited amplification, and thus, the bioorthogonal chemistry-based technique remained twoto threefold greater. This superior signal amplification has been attributed to the small size and high valency of the bioorthogonal reactants. The bioorthogonal cycloaddition between Tz and TCO has been shown to perform well in an intracellular environment using fluorescent molecules. Therefore, Haun et al. adapted the two-step nanoparticle detection scheme to target intracellular cancer biomarkers [43] . Fixed and permeabilized cancer cells were labeled with TCO-modified antibodies followed by Tz-MFNPs. As observed with extracellular biomarker targeting, the two-step bioorthogonal labeling strategy also supported signal amplification inside of cells, yielding a > 10-fold higher signal in comparison to direct immunoconjugates. Moreover, nanoparticle binding correlated closely with molecular expression levels determined by antibody staining and Western blot analysis (Figure 3 ). This included numerous cytoplasmic and nuclear proteins of interest for cancer, such as activated signaling molecules and growth indicators. Finally, the in situ bioorthogonal coupling technique was extended to quantum dots.
This two-step nanoparticle detection strategy was successfully adapted from cancer to bacterial pathogen detection. Liong et al. modified the antibodies that were highly selective for Staphylococcous aureus with TCO, and these antibodies bound specifically to their bacterial targets in human sputa [44] . Tz-magnetic nanoparticle probes were then efficiently coupled to TCO-antibodies via cycloaddition reaction to enable rapid and accurate detection of S. aureus. The bacterial signal was specific to S. aureus, as only the background signal was observed when detecting a panel of other bacteria.
Bacterial detection has also been extended to Grampositive pathogenic bacteria [45] . Antibiotics vancomycin and daptomycin, which are used to treat Gram-positive bacterial infections by binding to the bacterial cell wall and preventing cell wall synthesis, were modified with TCO. The antibiotics maintained the ability to bind to the bacterial cell wall after modification. In this study, synthesized antibiotics containing TCO moieties successfully bound to Gram-positive bacteria and were subsequently labeled with Tz-modified MFNPs (Figure 4 ) . So long as antibiotic concentrations were below 20 μ m to minimize bactericidal effects, Gram-positive bacteria were efficiently labeled with almost two orders of magnitude higher sensitivity than demonstrated with covalent nanoparticle conjugates. This labeling technique was even suitable for detecting Gram-positive bacteria within infected macrophages after semipermeabilization procedures.
The amplification of the nanoparticle signal beyond the two-step bioorthogonal scheme has been achieved using a layering approach [46] . This was accomplished using separate, alternating rounds of Tz-and TCO-modified nanoparticles. Peterson et al. first targeted extracellular cancer biomarkers by executing the standard TCO-antibody and Tz-MFNP steps. Subsequent reactions with TCO-MFNP and then Tz-MFNP resulted in nanoparticle clusters that exhibited a higher transverse relaxation rate, demonstrating an enhanced signal amplification ( Figure 5 ) . Moreover, the introduction of a cleavable dithiol bond between the MFNP and bioorthogonal reactant allowed the release of MFNP from cells using a reducing agent. The ability to separate the nanoparticles after targeting obviates the need to purify samples prior to detection, which could be advantageous for clinical applications. Indeed, nonpurified ascites derived from patients with pancreatic cancer exhibited 90 % of the signal observed in purified samples for the expression of EGFR, EpCAM, MUC-1, and HER2.
Clinical applications using in situ bioorthogonal nanoparticle labeling
Owing to the remarkable simplicity and signal amplification capabilities offered by the two-step, in situ bioorthogonal nanoparticle coupling technique, it was translated to clinical applications for molecular profiling of human cancer samples. This added sensitivity is critical for detecting cancer biomarkers because detailed molecular descriptions of tumors can assist in the diagnosis and treatment.
Haun et al. first used the TCO/Tz bioorthogonal coupling technique to amplify MNP binding to extracellular and intracellular cancer biomarkers for profiling tumor cells using a novel miniaturized diagnostic magnetic resonance device ( μ NMR) [47] . Tumor samples tested were obtained by fine-needle aspiration (FNA) biopsy from patients with suspected intra-abdominal tumors. The limited tissue sample available in FNAs, as well as the low expression levels of some proteins of interest, has prevented molecular analysis in the clinic. The bioorthogonal amplification/ μ NMR detection strategy, however, is highly sensitive and capable of accurately measuring the expression levels from sample sizes on the order of 100 -1000 cells [42, 43] . It is, therefore, well-suited to address the challenges of molecular diagnosis in the clinic. Indeed, single FNA specimens contained sufficient cellular material to detect nine different surface and intracellular biomarkers after dividing and labeling in parallel. Based on the quantitative biomarker expression results and evaluation of the consensus diagnosis for 50 patients, a panel of four biomarkers, MUC-1, HER2, EGFR, and EpCAM, was identified to provide the most accurate prediction of malignant disease. In fact, this four-protein malignancy signature had a higher diagnostic accuracy (96 % ) than conventional cytology of FNAs (74 % ) or even histopathology performed on much larger core biopsies (84 % ). In addition to being highly accurate, the bioorthogonal detection scheme had rapid turnaround time of less than an hour. The four-protein signature was then validated in a test set of 20 new patients, with 100 % accuracy. Recently, the Weissleder group applied the twostep, bioorthogonal coupling technique for protein biomarker-based detection drug treatment response monitoring of glioblastoma-derived microvesicles [48] . The microvesicles shed from glioblastomas have a molecular expression profile distinct from nontumor host microvesicles. This was exploited to distinguish tumor from nontumor microvesicles. The protein biomarkers on microvesicles were labeled with MNP using TCO/Tz bioorthogonal coupling and captured on a microfluidic device, followed by μ NMR detection to reveal protein expression levels. Notably, the treatment of patients with geldanamycin and TMZ decreased the total microvesicle count and reduced the expression profiles of the key biomarkers, EGF and EGFRvIII. This rapid detection strategy was capable of distinguishing a dose-dependent decrease in microvesicle counts as well as a decline in biomarker expression levels in a cell line model ( Figure 6 ). The authors applied this platform to track tumor progression in patients with GBM undergoing treatment and were successfully able to distinguish responder and nonresponder status after TMZ and radiation treatment.
Bioorthogonal amplification has also been used clinically to detect rare circulating tumor cells (CTCs) with higher diagnostic accuracy than the current clinical standard [49] . The two-step TCO/Tz bioorthogonal coupling was used to label CTCs with magnetic nanoparticles in whole blood, after red blood cells were lysed and removed. Magnetic signatures were then detected using a novel microfluidic chip outfitted with an array of eight micro-Hall sensors that was capable of detecting the magnetic moment of each passing cell. Flow focusing in conjunction with the micro-Hall sensor array produced a signal independent of the cell size and only proportional to the number of bound magnetic nanoparticles. The mean Hall voltage due to the magnetic nanoparticles was also proportional to the particle volume; therefore, multiple-sized particles yielded distinguishable signal peaks. This enabled multiplexed biomarker detection capacity in the micro-Hall detector chip. The blood samples derived from patients with advanced ovarian cancer were screened for EGFR, HER2, and MUC-1 with this detection approach, leading to the discovery of CTCs in 100 % of the samples and a diagnostic accuracy of 96 % . The current conventional approach, CellSearch, was also employed for comparison and was able to detect CTCs in only 20 % of the patients with 25 % diagnostic accuracy. Thus, the bioorthogonal nanoparticle amplification/ micro-Hall detector represents an exciting CTC detection strategy.
Conclusion and future work
In recent years, the targeted nanoparticle delivery vehicles and diagnostic sensors have shown potential for treating and detecting diseases. As we have discussed at length here, bioorthogonal chemistries have significantly advanced the capabilities of researchers to conjugate biomolecules to nanoparticle surfaces with exceptional efficiency and control. Moreover, the exquisite reaction speed and selectivity of the advanced bioorthogonal reactions has enabled in situ coupling to cells and significant amplification of nanoparticle binding. While these advancements have been exciting, we envision a number of areas where further improvements can be made. For example, there is continual need to improve detection sensitivity to enable the interrogation of low-level expression biomarkers or even mediators involved in downstream signaling pathways. To this point, bioorthogonal amplification has relied on the fortuitously large size of antibodies to provide a scaffold. Thus, precisely engineered scaffolds could provide for improved nanoparticle coupling yields and extension to diverse types of affinity molecules. Furthermore, multiplexing is the key area for improvements to be made because specificity is lost if one were to try and amplify multiple species with the TCO/Tz chemistry. Certainly, one avenue is to employ traditional nanoparticle conjugates with a single bioorthogonally amplified target. Another approach, however, would be to employ multiple bioorthogonal chemistries that are orthogonal to each other in concert. One such mutually orthogonal pairing has already been demonstrated for TCO/Tz and cyclooctyne/azide chemistries [30] . Finally, Deveraj et al. have established that the TCO/Tz chemistry can be utilized for in vivo detection of cancer using separate injections of TCO-antibody and a Tz-modified fluorescent polymer. Similar work using nanoparticles could establish whether bioorthogonal amplification is feasible in vivo for improved detection and drug delivery to tumors or other diseases.
